Epoetin Alfa Biosimilar in the Management of Chemotherapy-Induced Symptomatic Anemia in Haematology and Oncology

• Status: Completed
• Trial end date: 2011-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The main aim of this study is to observe correction of the hemoglobin level in the patients under chemotherapy, treated with epoetin alfa biosimilar and presenting with a solid tumor or a lymphoma or a myeloma.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hospira, Inc.; Hospira, now a wholly owned subsidiary of Pfizer
• Treatments: Epoetin Alfa

Criteria

Inclusion Criteria:

• Patients of more than 18 years of age

• Patients presenting with anemia following chemotherapy

• Patients suffer from solid tumours, malignant hemopathies, lymphomas or myelomas and presenting with anemia following chemotherapy

-- The patients may be included regardless of their chemotherapy cycle (from the first cycle until the last cycle)

• Patients eligible for epoetin alfa biosimilar treatment

Exclusion Criteria:

• Patients are not receiving chemotherapy

• Patients already included in an epoetin zeta trial

• Patients presenting with a contraindication to epoetin zeta

• Patients presenting with hypersensitivity to the active principle or any of the excipients

• Patient with erythroblastopenia or acquired pure red cell aplasia (APRCA)

• Patient with uncontrollable arterial hypertension

• Patients who cannot receive adequate prophylaxis by antithrombotic agents